

- D., et al. (2015). HIV-positive-to-HIV-positive kidney transplantation—results at 3 to 5 years. *New England Journal of Medicine*, 372:613–20.
- Neuhaus, J., Angus, B., Kowalska, J. D., et al. (2010). Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. *AIDS*, 24(5), 697–706.
- OPTN Policies and Bylaws. From <http://optn.transplant.hrsa.gov/policiesandbylaws/policies.asp>.
- Pais, R. & Benhamou, Y. (2010). Long-term therapy for chronic hepatitis B in HIV co-infected patients. *Gastroentérologie Clinique et Biologique*, 34, 136–41.
- Parsa, A., Kao, W. H. L., Xie, D., et al. (2013). *APOL1* risk variants, race, and progression of chronic kidney disease. *New England Journal of Medicine*, 369:2183–96.
- Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents; recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. (Accessed September 2015).
- Pelletier S. J., Norman S. P., Christensen L. L., et al. (2004). Review of transplantation in HIV patients during the HAART era. *Clinical Transplantation*, 63–82.
- Petrosillo, N., Chinello, P., & Cicalini, S. (2006). Pulmonary hypertension in individuals with HIV infection. *AIDS*, 20, 2128.
- Prevention, C. f. D. C. a. (2013). HIV Surveillance Supplemental Report.
- Ragni, M. V., Dodson, S. F., Hunt, S. C., et al. (1999). Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. *Blood*, 93, 1113–1114.
- Redd A. D., Quinn T. C., Tobian A. A. (2013). Frequency and implications of HIV superinfection. *The Lancet Infectious Diseases*, 13(7), 622–628.
- Reeves-Daniel, A. M., DePalma, J. A., Bleyer, A. J., Rocco, M. V., Murea, M., Adams, P. L., et al. (2011). The *APOL1* Gene and Allograft Survival after Transplantation. *American Journal of Transplantation*, 11(5), 1025–1030.
- Richterman, A., Blumberg, E., (2015). The challenges and promise of HIV-infected donors for solid organ transplantation. *Current Infectious Disease Reports*, 17:1–8.
- Richterman, A., Sawinski, D., Reese, P.P., et al. (2015). An assessment of HIV-infected patients dying in care for deceased organ donation in a United States urban center. *American Journal of Transplantation*, 15:2105–2116.
- Riella, L.V., Sheridan, A.M., (2015). Testing for high-risk *APOL1* alleles in potential living kidney donors. *American Journal of Kidney Disease*, (in press).
- Roland, M., Carlson, L., & Stock, P. (2002). Solid organ transplantation in HIV-infected individuals. *AIDS Clinical Care*, 14(7), 59–63.
- Roland, M. E., Adey, D., Carlson, L. L., & Terrault, N. A. (2003a). Kidney and liver transplantation in HIV-infected patients: case presentations and review. *AIDS Patient Care STDS*, 17(10), 501–507.
- Roland, M. E., Lo, B., Braff, J., & Stock, P. G. (2003b). Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. *Archives of Internal Medicine*, 163(15), 1773–1778.
- Roland, M. E., & Stock, P. G. (2003c). Review of solid-organ transplantation in HIV-infected patients. *Transplantation*, 75(4), 425–429.
- Sawinski, D., Goldberg, D. S., Blumberg, E., et al. (2015) Beyond the NIH multicenter HIV transplant trial experience: Outcomes of HIV+ liver transplant recipients compared to HCV+ or HIV+/HCV+ coinfecting recipients in the United States. *Clinical Infectious Disease*, (in Press).
- Sherman, K. E., Thomas, D., & Chung, R. T. (2014). Human immunodeficiency virus and liver disease forum 2012. *Hepatology*, 59(1), 307–317.
- Sims, D. B., Uriel, N., González-Costello, J., et al. (2011). Human immunodeficiency virus infection and left ventricular assist devices: a case series. *Journal of Heart and Lung Transplantation*, 30, 1060–1064.
- Soriano, V., Tuma, P., Labarga, P., et al. (2009). Hepatitis B in HIV patients: what is the current treatment and what are the challenges? *Journal of HIV Therapy*, 14(1), 13–18.
- Stock, P. G., Barin, B., Murphy, B., Hanto, D., Diego, J. M., Light, J., et al. (2010). Outcomes of kidney transplantation in HIV-infected recipients. *New England Journal of Medicine*, 363(21), 2004–2014.
- Taege, A. (2013). Organ transplantation and HIV progress or success? A review of current status. *Curr Infectious Disease Reports*, 15, 67–76.
- Tector, A. J., Mangu, R. S., Chestovich, P., et al. (2006). Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. *Annals of Surgery*, 244, 439–450.
- Terrault, N. A., Roland, M. E., Schiano, T., Dove, L., Wong, M. T., Poordad, F., et al. (2012). Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. *Liver Transplantation*, 18(6), 716–726.
- Touzot, M., Pillebout, E., Matignon, M., Tricot, L., Viard, J. P., Rondeau, E., et al. (2010). Renal transplantation in HIV-infected patients: the Paris experience. *American Journal of Transplantation*, 10(10), 2263–2269.
- Uriel, N., Jorde, U. P., Cotarlan, V., et al. (2009). Heart transplantation in human immunodeficiency virus-positive patients. *Journal of Heart and Lung Transplant*, 28, 667–669.
- Uriel, N., Nahumi, N., Colombo, P. C., et al. (2014). Advance heart failure in patients infected with human immunodeficiency virus: is there equal access to care? *Journal of Heart and Lung Transplantation* (in press, online).
- Wada, N., Jacobson, L. P., Cohen, M., French, A., Phair, J., & Munoz, A. (2013). Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984–2008. *American Journal of Epidemiology*, 177(2), 116–125.
- Wada, N., Jacobson, L. P., Cohen, M., French, A., Phair, J., & Munoz, A. (2014). Cause-specific mortality among HIV-infected individuals, by CD4 (+) cell count at HAART initiation, compared with HIV-uninfected individuals. *AIDS*, 28(2), 257–265.
- Yoon, S. C., Hurst, F. P., Jindal, R. M., George, S. A., Neff, R. T., Agodoa, L. Y., et al. (2011). Trends in renal transplantation in patients with human immunodeficiency virus infection: an analysis of the United States renal data system. *Transplantation*, 91(8), 864–868.

Dated: November 20, 2015.

Francis S. Collins,

Director, National Institutes of Health.

[FR Doc. 2015–30172 Filed 11–24–15; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Reproductive Biology.

Date: December 8, 2015.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Michael Knecht, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 6176, MSC 7892, Bethesda, MD 20892, (301) 435-1046, knechtm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Vascular Biology and Hematology AREA.

Date: December 18, 2015.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Larry Pinkus, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD 20892, (301) 435-1214, pinkusl@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 19, 2015.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015-29940 Filed 11-24-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the NHLBI Institutional Training Mechanism Review Committee, December 11, 2015, 8:00 a.m. to December 11, 2015, 5:00 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on November 12, 2015, 80 FR 69975.

This meeting is being amended because the meeting will now start at 10 a.m. and will be conducted as a teleconference. The meeting is closed to the public.

Dated: November 19, 2015.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015-29941 Filed 11-24-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA-2015-0001]

Changes in Flood Hazard Determinations

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Final notice.

SUMMARY: New or modified Base (1-percent annual chance) Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, and/or regulatory floodways (hereinafter referred to as flood hazard determinations) as shown on the indicated Letter of Map Revision (LOMR) for each of the communities listed in the table below are finalized. Each LOMR revises the Flood Insurance Rate Maps (FIRMs), and in some cases the Flood Insurance Study (FIS) reports, currently in effect for the listed communities. The flood hazard determinations modified by each LOMR will be used to calculate flood insurance premium rates for new buildings and their contents.

DATES: The effective date for each LOMR is indicated in the table below.

ADDRESSES: Each LOMR is available for inspection at both the respective Community Map Repository address listed in the table below and online through the FEMA Map Service Center at www.msc.fema.gov.

FOR FURTHER INFORMATION CONTACT: Luis Rodriguez, Chief, Engineering Management Branch, Federal Insurance and Mitigation Administration, FEMA, 500 C Street SW., Washington, DC 20472, (202) 646-4064, or (email) Luis.Rodriguez3@fema.dhs.gov; or visit the FEMA Map Information eXchange (FMIX) online at www.floodmaps.fema.gov/fhm/fmx_main.html.

SUPPLEMENTARY INFORMATION: The Federal Emergency Management Agency (FEMA) makes the final flood hazard determinations as shown in the LOMRs for each community listed in the table below. Notice of these modified flood hazard determinations has been published in newspapers of local circulation and 90 days have elapsed

since that publication. The Deputy Associate Administrator for Mitigation has resolved any appeals resulting from this notification.

The modified flood hazard determinations are made pursuant to section 206 of the Flood Disaster Protection Act of 1973, 42 U.S.C. 4105, and are in accordance with the National Flood Insurance Act of 1968, 42 U.S.C. 4001 *et seq.*, and with 44 CFR part 65.

For rating purposes, the currently effective community number is shown and must be used for all new policies and renewals.

The new or modified flood hazard information is the basis for the floodplain management measures that the community is required either to adopt or to show evidence of being already in effect in order to remain qualified for participation in the National Flood Insurance Program (NFIP).

This new or modified flood hazard information, together with the floodplain management criteria required by 44 CFR 60.3, are the minimum that are required. They should not be construed to mean that the community must change any existing ordinances that are more stringent in their floodplain management requirements. The community may at any time enact stricter requirements of its own or pursuant to policies established by other Federal, State, or regional entities.

This new or modified flood hazard determinations are used to meet the floodplain management requirements of the NFIP and also are used to calculate the appropriate flood insurance premium rates for new buildings, and for the contents in those buildings. The changes in flood hazard determinations are in accordance with 44 CFR 65.4.

Interested lessees and owners of real property are encouraged to review the final flood hazard information available at the address cited below for each community or online through the FEMA Map Service Center at www.msc.fema.gov.

(Catalog of Federal Domestic Assistance No. 97.022, "Flood Insurance.")

Dated: October 30, 2015.

Roy E. Wright,

Deputy Associate Administrator for Insurance and Mitigation, Department of Homeland Security, Federal Emergency Management Agency.